Table 1.
Participant Characteristics. Mean (SD)
| Schizophrenia Younger (n=29) |
Control Younger (n=40) |
Schizophrenia Older (n=31) |
Control Older (n=37) |
|
|---|---|---|---|---|
| Gender Male/Female |
20/9 |
20/20 |
19/12 |
25/12 |
| Age (years) | 25.7 (4.3) | 25.3 (4.6) | 48.3 (5.8) | 51.0 (6.0) |
| 1Education (years) | 13.3 (2.1) | 14.4 (2.2) | 12.7(2.0) | 14.9 (2.4) |
| 2Smoking status (yes/no) | 12/17 | 10/30 | 12/19 | 9/28 |
| 1.3Processing speed (digit sequencing test) | 63.7 (20.6) | 72.0 (19.3) | 50.4(15.3) | 64.4 (19.5) |
| 1,3 Functional Capacity (UPSA) | 94. 7 (11.5) | 104.2 (7.4) | 85.43 (14.8) | 101.06 (10.4) |
| 1Working memory (digit symbol coding test) | 42.9 (12.1) | 46.1 (13.0) | 35.6 (13.6) | 47.3 (11.2) |
| Duration of illness (years) | 5.6 (4.6) | 24.0 (9.8) | ||
| Psychiatric Ratings BNSS |
15.6 (12.1) |
17.6 (15.4) |
||
| BPRS (total) | 39.2 (10.5) | 38.3 (11.5) | ||
| BPRS (+ subscale) | 8.4 (4.4) | 8.6 (4.6) | ||
| BPRS (− subscale) | 6.6 (2.7) | 6.2 (2.4) | ||
| Chlorpromazine units (CPZ) | 562.0 (511.4) | 668.9 (643.9) | ||
| Antipsychotic Medication Typical Atypical Both typical and atypical None |
1 25 1 2 |
4 18 6 3 |
1
Main effect of diagnostic group (schizophrenia < control; p < 0.05)
2
Chi square (schizophrenia > control; p < 0.05)
3
Main effect of age group (older < younger; p < 0.05)